How a new eczema medication works in real-world patient care

This is a real-world study that tracks how a medication called abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis). Rather than testing the drug in a controlled lab setting, researchers want to see how it actually performs when doctors prescribe it in regular clinical practice. Over 12 months, the study will collect information about how patients respond to the treatment and how doctors use it to care for their patients.

While this medication has been tested and approved, doctors and patients want to understand how well it works in real-world conditions—not just in clinical trials. This study fills that gap by gathering information about treatment patterns and outcomes to help guide better care decisions for people with moderate-to-severe eczema.